Mark Eisner

Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology with a rich background at Genentech and UCSF, shares insights on the company's shift to focus on infectious diseases and oncology post-COVID. He discusses the strategic integration of Sanofi's T-cell engager platform and the prioritization of hepatitis programs. Eisner also reflects on his journey from academic medicine to biopharma, emphasizing the importance of leadership during organizational changes and the potential of innovative partnerships in drug development.